Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Maze Therapeutics, Inc.NASDAQ: MAZE
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows in line with its trailing trend
Q1 FY2026 operating expenses of $46.11M rose 30.2% year over year, in line with the +30.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +30.2% holds above the trailing-twelve-month pace of +30.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 140.5M USD
- Year-over-year change
- +27.8%
- 3-year CAGR
- +8.2%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140.5M | +27.8% |
| FY2024 | 2024-12-31 | 109.91M | +11.5% |
| FY2023 | 2023-12-31 | 98.55M | -11.2% |
| FY2022 | 2022-12-31 | 111.03M | — |
Operating Expenses vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +30.0% is the 4th highest of 8, against a peer median of +28.7%.
- Operating expenses amounts to 762.3% of revenue for MAZE, versus a peer median of 145.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $753.04M USD | +45.8% | +8.5% | 115.7% | |
| LTM Jun 2026 | $712.31M USD | -28.4% | -10.0% | 70.6% | |
| LTM Mar 2026 | $430.6M USD | +25.0% | +53.7% | 100.7% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $169.24M USD | +70.9% | — | 175.8% |
| LTM Mar 2026 | $152.46M USD | +30.0% | +8.2% | 762.3% | |
| FY2025 | €137.37M EUR | +28.7% | +22.8% | 3064.2% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $111.96M USD | +34.4% | +36.6% | 1085.3% |
| LTM Mar 2026 | $36.74M USD | +26.3% | +34.9% | — | |
| Peer median (excluding MAZE) | — | +28.7% | +28.9% | 145.7% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.